regulatory status comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
=== Theobromine and oxalate === Chocolate may be a factor for heartburn in some people because one of its constituents, theobromine, may affect the esophageal sphincter muscle in a way that permits stomach acids to enter the esophagus. Theobromine poisoning is an overdosage reaction to the bitter alkaloid, which happens more frequently in domestic animals than humans. However, daily intake of 50–100 g cocoa (0.8–1.5 g theobromine) by humans has been associated with sweating, trembling, and severe headache. Chocolate and cocoa contain moderate to high amounts of oxalate, which may increase the risk of kidney stones.
=== Deputy Leaders of the Liberal Party in the House of Commons === Donald Maclean (1920–1922) John Simon (1922–1924) Post vacant (1924–1929) Herbert Samuel (1929–1931) Archibald Sinclair (1931–1935) Francis Dyke Acland (1935–1939) Post vacant (1939–1940) Percy Harris (1940–1945) Post vacant (1945–1949) Megan Lloyd George (1949–1951) Post vacant (1951–1962) Donald Wade (1962–1964) Post vacant (1964–1976) John Pardoe (1976–1979) Post vacant (1979–1985) Alan Beith (1985–1988)
=== Films and television === Bhopal Express, 1999 film. "Bhopal Nightmare" (2011), the sixth episode of season 4 of the television docudrama series Seconds from Disaster. In 2014, to coincide with the 30th anniversary of the disaster, the historical drama Bhopal: A Prayer for Rain was released, starring Martin Sheen as Union Carbide CEO Warren Anderson, Kal Penn, and Mischa Barton. The Railway Men: The Untold Story of Bhopal 1984 starring KK Menon, R Madhavan, Divyendu Sharma and Babil Khan is a four-part web series that was released on 18 November 2023 on Netflix.
=== Neurodegenerative disorders === Huntington disease. No reliable conclusion could be drawn regarding the effectiveness of THC or oral cannabis extract in treating the symptoms of Huntington disease as the available trials were too small to reliably detect any difference Parkinson's disease. Based on a single study, oral CBD extract was rated probably ineffective in treating levodopa-induced dyskinesia in Parkinson's disease. Alzheimer's disease. A 2009 Cochrane Review found insufficient evidence to conclude whether cannabis products have any utility in the treatment of Alzheimer's disease.
Sources: en.wikipedia.org
Jon Wiederhorn of Rolling Stone called the album "liberating and enlightening, the songs achieve a startling, staggering and palpable impact." The band released the home video The Nona Tapes On December 12, a mockumentary featuring interviews with the band members conducted by journalist Nona Weisbaum (played by Jerry Cantrell), and the music video for "Grind". The band opted not to tour in support of Alice in Chains, adding to the rumors of drug abuse. The song "Got Me Wrong" unexpectedly charted three years after its release on the Sap EP. The song was re-released as a single on the soundtrack for the film Clerks in 1994, reaching number seven on the Mainstream Rock Tracks chart. Alice in Chains resurfaced on April 10, 1996, to perform for MTV Unplugged, a program featuring all-acoustic set lists. The performance featured some of the band's highest-charting singles, including "Rooster", "Down in a Hole", "Heaven Beside You", "No Excuses" and "Would?", and introduced a new song, "Killer Is Me", with Cantrell on lead vocals. The show marked Alice in Chains' only appearance as a five-piece band, adding second guitarist Scott Olson. A live album of the performance was released in July 1996, which debuted at number three on the Billboard 200, and was accompanied by a home video release, both of which received platinum certification by the RIAA. The band also appeared on The Late Show with David Letterman on May 10, 1996, performing the songs "Again" and "We Die Young".
=== 1960s === During the 1960s, the main conflict in Colombia was between leftist guerillas and the central government. Key concerns included access to land, the battle between communist and far-right ideologies, and the marginalization of peasant populations. In the early 1960s, Colombian Army units loyal to the National Front began to attack peasant communities. This happened throughout Colombia, with the Colombian army deeming these peasant communities as enclaves for bandits and communists. It was the 1964 attack on the community of Marquetalia that motivated the later creation of FARC. Despite the infantry and police encirclement of the villages inside Marquetalia (3,500 men swept through the area), Manuel Marulanda managed to escape the army cordon. Unlike the rural FARC, which had roots in previous Liberal peasant struggles, the National Liberation Army (ELN) was mostly an outgrowth of university unrest. It would subsequently tend to follow a small group of charismatic leaders, including Camilo Torres Restrepo. Both guerrilla groups remained mostly operational in remote areas of the country during the rest of the 1960s. The Colombian government organized several short-lived counter-guerrilla campaigns in the late 1950s and early 1960s. The U.S. government and the CIA aided these efforts, which employed hunter-killer teams and involved U.S. personnel from the previous Philippine campaign against the Huks, who would later participate in the subsequent Phoenix Program in the Vietnam War.
Monocryl is a synthetic, absorbable suture manufactured in Cornelia, Georgia, USA, and trademarked by Ethicon. It is composed of poliglecaprone 25, which is a copolymer of glycolide and ε-caprolactone. It comes both dyed (violet) and undyed (clear) and is an absorbable monofilament suture. It is generally used for soft-tissue approximation and ligation. It is used frequently for subcuticular dermis closures of the face. It has less of a tendency to exit through the skin after it breaks down, in contrast to Vicryl. It is contraindicated for use in cardiovascular and neurologic tissues and for usage in ophthalmic and microsurgery. The use of poliglecaprone suture may be inappropriate in patients who are older, malnourished, or debilitated, as well as in patients with conditions that may delay wound healing. Monocryl has a low tissue reactivity, maintains high tensile strength, and has a half-life of 7 to 14 days. At 1 week, its in vivo tensile strength is at 50–60% undyed (60–70% dyed), 20–30% undyed (30–40% dyed) at two weeks, and essentially completely hydrolyzed by 91–119 days. When removed from the package, it has a high degree of "memory", or coil. It is slippery, making it easier to pass than a braided suture. It has a consistency close to nylon suture material. It is rarely used for percutaneous skin closure and is not used in areas of high tension (e.g., fascia).
Sources: en.wikipedia.org
=== Insecticidal properties === Capsaicin deters insects in multiple ways. The first is by deterring insects from laying their eggs on the pepper due to the effects capsaicin has on these insects. Capsaicin can cause intestinal dysplasia upon ingestion, disrupting insect metabolism and causing damage to cell membranes within the insect. This in turn disrupts the standard feeding response of insects.
== Environmental cleanup == There have been many attempts to eliminate perchlorate contamination. Current remediation technologies for perchlorate have downsides of high costs and difficulty in operation. Thus, there have been interests in developing systems that would offer economic and green alternatives.
Two days later, mass armed attacks occurred throughout the country, including the storming of a television station during a live broadcast. The left-wing opposition supported the government, saying: "Now is the time for national unity. Organized crime has declared war on the state, and the state must prevail". Some analysts criticized Noboa for providing an exclusively security-based response to crime, without making any announcements on possible reforms of the police and judiciary, reputed to be highly corrupt, or on social policies to combat the root causes of violence. Amid the conflict, a series of human rights violations were denounced. The lack of regulation and the way in which security measures were implemented resulted in allegations of human rights violations from local and international civil society organizations such as the Alianza por los Derechos Humanos de Ecuador and Human Rights Watch. In mid-2024, the United Nations Committee Against Torture noted its concern over allegations about the management of the crisis and the treatment of detainees by Ecuadorian security forces. In 2025, the nation's Permanent Committee for the Defense of Human Rights issued a report on the potential cases of 27 people victims of forced disappearance by state forces. The PROGEN case in Ecuador has also sparked a scandal due to a $149 million contract signed by the government for the purchase of thermal generators. Amid an energy crisis, delays and the lack of transparency in the process have worsened the situation, leaving the country without the promised 150 megawatts.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.